Myelodysplastic Syndrome
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-06-22Clinical Trial Update: Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia [Phase 1]
A Phase 1 clinical trial evaluating total marrow and lymphoid irradiation with chemotherapy before donor transplantation in patients with my…
-
CLINICAL_TRIALS trial_result · 2025-06-15Clinical Trial Update: Evaluation of 3 Different Doses of IV Busulfan [Phase 2]
Clinical Trial Update on a Phase 2 study evaluating three different doses of intravenous busulfan in patients with myelodysplastic syndrome …
-
CLINICAL_TRIALS trial_result · 2025-06-13Clinical Trial Update: Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome [Phase 3]
Phase 3 trial evaluating response-based chemotherapy in younger patients with Down syndrome who have newly diagnosed acute myeloid leukemia …
-
CLINICAL_TRIALS trial_result · 2025-06-04Clinical Trial Update: Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation [Phase 2]
Phase 2 trial comparing three GVHD prophylaxis regimens in nonmyeloablative or reduced-intensity conditioning unrelated donor transplantatio…
-
CLINICAL_TRIALS trial_result · 2025-05-25Clinical Trial Update: Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza [Phase 1]
Phase 1 blinded cross-over bioequivalence trial comparing Luitpold azacitidine with Vidaza has completed, with results posted.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-05-23Clinical Trial Update: DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia [Phase 1, Phase 2]
A phase 1/2 study of DS-1594b with or without azacitidine, venetoclax, or mini-HCVD in relapsed or refractory acute myeloid leukemia or acut…
-
CLINICAL_TRIALS trial_result · 2025-05-18Clinical Trial Update: Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS [Phase 1]
A Phase 1 study from Novartis evaluating PDR001 and MBG453 with decitabine in acute myeloid leukemia or high-risk myelodysplastic syndromes …
-
CLINICAL_TRIALS trial_result · 2025-04-29Clinical Trial Update: IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation [EARLY_Phase 1]
A Phase 1 trial evaluating interferon-gamma (IFN-γ) for relapsed myelodysplastic syndrome and acute myeloid leukemia after allogeneic stem c…
-
CLINICAL_TRIALS trial_result · 2025-04-22Clinical Trial Update: Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating a three-drug combination of azacitidine, venetoclax, and trametinib for relapsed or refractory acute myeloid leukem…
-
CLINICAL_TRIALS trial_result · 2025-04-15Clinical Trial Update: AZA+Lus VS AZA Monotherapy in HR-MDS [Phase 3]
Phase 3 trial comparing azacitidine plus Lus versus azacitidine monotherapy in higher-risk myelodysplastic syndrome; the study is not yet re…
-
CLINICAL_TRIALS trial_result · 2025-04-02Clinical Trial Update: Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders [Phase 1]
Phase 1 study of Veliparib with Topotecan, with or without Carboplatin, in relapsed or refractory acute leukemias, high-risk myelodysplastic…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation [Phase 2]
Phase 2 trial evaluating olaparib for relapsed/refractory IDH-mutated acute myeloid leukemia or myelodysplastic syndrome; results posted 202…
-
CLINICAL_TRIALS trial_result · 2025-03-25Clinical Trial Update: A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS [Phase 1]
Phase 1, open-label study of intravenous GSK3745417 in relapsed/refractory myeloid malignancies (AML and high-risk myelodysplastic syndrome)…
-
CLINICAL_TRIALS trial_result · 2025-03-20Clinical Trial Update: Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies [Phase 2]
This Phase 2 trial investigates reduced-intensity chemotherapy and radiation therapy before donor stem cell transplantation for various hema…
-
CLINICAL_TRIALS trial_result · 2025-02-28Clinical Trial Update: Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) [Phase 1]
Phase 1 study evaluating ruxolitinib in patients with low or intermediate-1 risk myelodysplastic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies [Phase 1]
Phase 1 study evaluating APR-246 in combination with venetoclax and azacitidine for TP53-mutant myeloid malignancies has completed and poste…
-
CLINICAL_TRIALS trial_result · 2025-01-01Clinical Trial Update: Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers [Phase 2]
Phase 2 trial evaluating cord blood transplant with Dilanubicel for HIV-positive hematologic cancers; the study was terminated and results w…
-
CLINICAL_TRIALS trial_result · 2024-12-13Clinical Trial Update: A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 2]
A biomarker-directed Phase 2 trial of tamibarotene (SY-1425) in acute myeloid leukemia and myelodysplastic syndrome has completed and posted…
-
CLINICAL_TRIALS trial_result · 2024-12-06Clinical Trial Update: Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) [Phase 2]
Phase 2 clinical trial update of flotetuzumab for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell tr…
-
CLINICAL_TRIALS trial_result · 2024-11-18Clinical Trial Update: Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant [Phase 1]
Phase 1 clinical trial evaluating single-agent and combined inhibition after allogeneic stem cell transplant in patients with acute myeloid …
-
CLINICAL_TRIALS trial_result · 2024-11-04Clinical Trial Update: Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia [Phase 2]
Phase 2 trial testing nivolumab and azacitidine with or without ipilimumab for refractory/relapsed or newly diagnosed acute myeloid leukemia…
-
CLINICAL_TRIALS trial_result · 2024-10-30Clinical Trial Update: Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation [Phase 2]
Phase 2 clinical trial update on a Triplex CMV vaccine designed to prevent CMV infection in patients undergoing hematopoietic stem cell tran…
-
CLINICAL_TRIALS trial_result · 2024-10-21Clinical Trial Update: Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) [Phase 2]
Phase 2 trial of a cytomegalovirus vaccine for donors and recipients undergoing allogeneic hematopoietic cell transplantation has completed,…
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents [Phase 1]
Phase 1 results assess safety and preliminary efficacy of combining pembrolizumab with entinostat in patients with myelodysplastic syndrome …
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: VA as Maintenance Therapy Post Allo-HSCT in MDS and AML [Phase 2]
A Phase 2 trial evaluating VA as maintenance therapy after allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome a…